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(i.e. beta blockers), and SP has been prescribed to a broad population of HF patients. 
We sought to define the incidence of HK and RI with SP therapy in HF patients in our 
clinicat practice. 
Methods: We studied clinical data from 926 consecutive patients with HF started on SP 
from 1996 to 2002. We compared baseline characteristics, medications & laboratory data 
at selected time points on 126 randomly selected controls and 67 (7.2%) cases (SP was 
stopped due to HK - >B.OmEqlL or RI - creatinine >= 2.5 mg/dL). Between group compar- 
ison was done using non-parametric Mann-Whitney tests. Multivariate logistic regression 
was performed to Identify independent predictors of HK and RI. Data are expressed as 
mean + s.d., p value. 
Results: Analysis of the study subjects (age 59 f 13, female 37%, ejectlon fraction 0.25 
* 0.13, angiotensin converting enzyme inhibitors 94%, beta blockers 64%) revealed that, 
compared to controls, cases were older (63 f 10 vs 57 * 14, 0.002), had lower New York 
Heart Association class (2.4 * 0.5 vs 2.6 t 0.7, 0.04), had higher baseline serum glucose 
(144 i 72 vs 124 + 63 mg/dL, O.Ol), potassium (4.4 kO.4 vs 4.3 t 0.5 mEq/L, 0.02), and 
creatinine (1.3 * 0.3 vs 1.2 * 0.3 mg/dL, 0.02). and were more likely to be treated with 
beta blockers (96% vs 79%, 0.002) and thiazide diuretics (43% vs 29%, 0.04). Indepen- 
dent predictors of HK included age, beta blocker use, diabetes and baseline potassium 
dosage, while independent predictors of RI included thiazide diuretic use and baseline 
creatinine. 
(w56) 
Baseline parameters 
Age (years) 56 
Gender-Male 41(72%) 
Systolic pressure (.SP)(mm Hg) 115 
Sodium (mEqlL) 137 
Blood Urea Nitrogen (BUN) 50 
Serum Creatinine (mg/dL) 1.97 
Ejection Fraction 16 
QRS duration 152 
Using ACEI or ARB (%) 93% 
Using Beta Blockers (%) 59% 
Results (admission to discharge) 
Change in BUN -1.9 
Change in Creatinine -0.11 
Change in Weight (pounds) 10.5 
LOS (days) 2.67 
(n=72) 
66 0.07 
36(55%) 0.04 
126 0.011 
137 0.759 
40 0.067 
1.57 0.023 
24 0.023 
130 0.005 
66.5% 0.54 
69% 0.45 
-1.4 0.643 
-0.01 0.636 
11 0.740 
3.79 0.002 
Conclusion: Although the Nes Group was more ill, LOS was significantly shorter for this 
group. In addition use of Nes resulted in no significant change in renal function, same 
decrease in weight in a shorter period of time. Thus, use of Nes as initial therapy may 
allow more rapid discharge of patients without compromising renal function 
1085-72 Discordant Prescription of Guideline-Directed Therapy 
for Heart Failure Between Subspecialties of Cardiology 
Marv N. Walsh, Cynthia D. Adams, The Care Group, LLC, Indianapolis, IN 
Background: The updated ACCIAHA guidelines for management of heart failure (HF) 
clearly describe the mortality and morbidity benefits associated with beta blockers (BB) 
and ACE inhibitors in HF. In spite of wide dissemination of these data, variability in 
adherence likely exists. The purpose of this study was to examine practice patterns 
among cardiologists with regard to prescription of BB and either ACE inhibitors or angio- 
tensin II receptor blockers (ACE) in HF patients (pts). 
Methods: The electronic medical record (EMR) at a large, urban cardiology practice was 
queried to report BB and ACE use in pts with diagnoses of HF or cardiomyopathy. The 
ability of the EMR to select pts by diagnosis, sort by physician, and identify medications, 
enabled examination of variability in prescribing practices. 
Results: 1956 pts with appropriate diagnoses were examined. 57% were prescribed BB; 
75% ACE; and 46% both. The range of BB use among individual physicians was 20. 
94%; ACE 44-93%: and both 14.67%. Comparison between subspecialists is outlined 
below. 
HF 
Non-invasive 
69% 
Invsslve 
Interventional 
Electrophysiologists 
BB 
ACE 
63% 
43% 
71% 
55% 
71% 
50% 
71% 
57% 
BB+ACE 
61% 
32% 
47% 
41% 
Conclusion: Wide variation was found in the prescription of BB and ACE in HF pts 
among cardiology subspecialties. HF specialists most closely adhered to guidelines. 
Most notably, BB plus ACE was prescribed in 61% of pts by HF specialists, compared to 
only 3247% by other cardiologists. These data clearly show the need for increased 
awareness of guideline-directed therapy, even among cardiologists. Such feedback may 
enhance appropriate use of proven therapies. 
1085-73 Splronolactone Induced Renal Impairment and 
Hyperkalemia in Patients With Heart Failure: Can We 
Predict These Side Effects? 
Kamala P. Tamirisa, Keith D. Aaronson, Robert J. Cody, Todd M. Koellin$. University of 
Michigan, Ann Arbor, Ml 
Background: Clinical trials evaluating the effects of spironolactone (SP) in heart failure 
(HF) reported that 2% of patients required discontinuation of SP due to hyperkalemia 
(HK) or renal impairment (RI). Medical therapy for HF has evolved since these studies 
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Conclusions: SP induced HK and RI are more common in our clinical experience than 
reported previously. This difference may be partially explained by the frequent use of 
beta blockers to treat HF and concomitant medications and comorbidities. Redoubled 
efforts are necessary to protect patients against these infrequent yet serious side effects 
of SP. 
1085-74 Do Patients Necessarily Have to Start With an 
Angiotension Converting Enzyme Inhibitor In the 
Treatment of Heart Failure? Results of the CARMEN 
(Carvediloi ACE Inhibitor Remodeling Mild CHF 
EvalustloN) Study 
Willem J. Remme, Guenther Riegger, Per Hildebrandt, Michel Komajda, Marco Bobbio, 
Jordi Soler-Soler, Wybren Jaarsma, Stuart Pocock, Lars Ryden, on behalf of the 
CARMEN investigators, Sticares, Rotterdam, The Netherlands 
Background: Treatment guidelines for chronic hean failure (CHF) recommend ACE- 
inhibitor (ACE-I) as first-line treatment and eblcckers are to be added in case patients 
remain symptomatic. This paradigm, based on historical grounds, enforces polyphar- 
macy and prevents an individualized approach to the treatment of CHF. The aims of the 
CARMEN trial were to challenge this paradigm by comparing the effect on cardiac 
remodeling of the ACE-I Enalapril (E) against Carvedilol (C) a combined PI/&- blocker 
with additional a, -receptor blockade and antioxidant properties. 
Methods: CARMEN is a parallel-group, 3.arm, double-dummy, multi-center study con- 
ducted in 13 European countries. Patients were randomized to C&E, C or E treatment, 
uptitrated on C to 25mg (50mg in patients _> 65kg) bid target dose and/or E to 1Omg bid 
target dose, and continued for 16 months. In the C&E treated arm. C was uptitrated first. 
Effects on left ventricular (LV) remodeling were assessed by serial transthoracic 
echocardiography (biplane, Simpson) at baseline, months 6, 12 and 16 at a central core 
laboratory. 
Results: The ITT population included 479 mild (NYHA II = 65%, LV ejection fraction (EF) 
<40%) CHF patients (C&E = 156; C = 161; E = 160), 61% male, mean age 62 years. LV 
end systolic volume index (LVESVI) was reduced by 5.4 ml/m* (p=O.O015), LV end dias- 
tolic volume index by 5.0 ml/m2 (p=O.OOSS) and LVEF increased by 2.3% (p=O.O022) at 
month 16 for the primary comparison favoring C&E versus E. The second primary com- 
parison favored C versus E, although differences were not significant. However, in the 
within-group comparison C significantly reduced LVESVI by 2.6 mVm2 (p=O.O16) corn- 
pared to baseline, whereas no changes were observed in E, and LVESVI decreased by 
6.3 ml/ m2 (p=O.OOOl) in C&E. 
All three arm showed very similar safety profiles and withdrawal rates. 
Conclusion: The CARMEN results confirm the current treatment guidelines and provide 
an immediate mandate for prescribing the combination of ACE-I and C in mild CHF 
patients. However, as C was safely initiated before ACE-I and resulted in reversed LV 
remodeling, one might challenge the historical sequence of ACE-I as first-line therapy 
and start treatment with Carvedilol before ACE-I. 
1085-75 Double Blind, Placebo-Controlled Study of Long-Term 
Intermittent Dobutamine Infusion With Concomitant 
Oral Amiodsrone for End Stage Heart Failure 
Eleftheria Tsagalou, Maria Anastasiou-Nana, George Alexopoulos, John Terrovitis, 
Konstantinos Chalkias, Christos Gialamas, Konstantinos Christodoulou, John Kanakakis, 
John N. Nanas. University of Athens, Athens, Greece 
Background: Agents with positive inotropic affect have consistently been shown to 
increase mortality when administered chronically to patients with congestive heart failure 
(CHF). A non randomized study has showed that long-term intermittent dobutamine infu- 
sion (IDI) combined with oral amiodarone, improves the sumival of patients with end 
stage CHF .The purpose of this randomized double blind study was to evaluate prospec- 
tively the effects of long-term IDI combined with oral amiodarone in patients with CHF, 
refractory to slandard medical treatment. Methods: Thirty patients with decompensated 
CHF refractory to standard treatment were randomized in a double blind manner to 
receive for 6 hours every 14 days intravenous infusion of placebo (Group 1, n=14), or 
dobutamme lOpg/kg/min, (Group 2, n=l6). All patients were treated with oral amio- 
darone, 400mgld, started at least 2 weeks before randomization. Results: There ware 
no differences in baseline clinical, hemodynamic and biochemical characteristics 
between the two groups. The left ventricular ejection fraction was 24 i5 % and 23+6% in 
Group 1 and 2 respectively (~~0.563); mean pulmonary capillary wedge pressure 30*6 
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mmHg and 28*8 mmHg (p=O.528); systolic blood pressure 98+13mmHg and 
99+18mmHg (p=O.839); cardiac index 2.2+0.71Vmin/m2 and 2.1+0.61t/min/m2 (p=O.719). 
Kaplan-M&r sul~wal analysis showed a 60% reduction in the risk of death from any 
cause in the group treated with the combination of dobutemine and amiodarone, com- 
pared with the group treated with placebo and amiodarone (hazard ratio 0.403; 95% con- 
fidence interval 0.164-0.992, p=O.O48). The 1. and P-year survival rates were 69% and 
44%, in the dobutamine-treated group, versus 28% and 21%, respectively, in the pla- 
cebo-treated group (pcO.05 for both comparisons). Median su~lvals were 574 and 144 
days in Groups 2 and 1, respectively. At six months,‘the NYHA functional class was sig- 
nificantly Improved in the surviving patients of both groups. Conclusion: Long-term IDI 
combined with amiodarone, added to conventional treatment, improves survival of 
patients with severe CHF. 
the magnitude of that benefit is signficantly less than that observed in non-DM CHF pts. 
Therefore, all eligible pts wth symptomatic CHF, regardless of their DM status, should 
receive BBS for their prognostic benefits. 
All-Cause Mortabty: Diabetic vs Non-Diabetic Patients 
1085-76 Statin Therapy Is Associated With Improved Survival in 
lschemic and Nonischemic Heart Failure 
Tamara 8. Horwich, Michele A. Hamilton, Robb MacLellan, Jignesh Patel, Mary 
Lesniewski, Gregg C. Fonarow. University of California Los Angeles Medical Center, Los 
Angeles, CA 
Study 
BEST 
US CaNedilol 
CIBIS II 
COPERNICUS 
MERIT-HF 
Total 
Diabetics Non-Diabetics 
N RR 95% Cl r; RR 95% Cl 
964 0.95 0.80, 1.12 1744 0.89 0.77, 1.02 
307 0.37 0.14,0.93 772 0.44 0.23, 0.86 
312 0.81 0.52. 1.27 2335 0.68 0.55, 0.82 
589 0.68 0.46, 0.99 1700 0.67 0.53, 0.85 
984 0.82 0.58, 1.17 3007 0.58 0.46, 0.74 
3156 0.85 0.74,0.97 9558 0.72 0.65, 0.79 
1085-78 
Background: Although HMG CoA reductase inhibitors (statins) are known to decrease 
mortality in CHD, concern has been raised about potential negative effects in patients 
with heart failure (HF). The impact of statins on the progression of advanced HF has not 
been studied. 
Electrophysiologic Alterations Seen in Patients With 
Advanced Cardiac Failure After Angiotension 
Converting Enzyme Inhibitor Therapy 
Methods: We retrospectively studied a cohort of 251 pts with advanced HF referred for 
management and transplant evaluation. Pts without adequate documentation of medical 
regimen (n=33) were excluded from analysis. Survival free from death or urgent trans- 
plant was determined. 
Results: Mean age, EF, and total cholesterol (TC) were 52,25%, and 165 mg/dl, respec- 
tively. Fifty-one % of pts were on statin Rx. CAD was etiology of HF in 52% of patients, 
79% of whom were on statin Rx. In non-CAD HF pts. 28% were on statin Rx. Pis on 
statins were significantly older, and had higher rates of CAD, smoking, HTN, and DM. 
Treated and non-treated pts were similar in NYHA. LVEF, sex. BMI, TC, and HF medica- 
tions. Pts on statin Rx had improved survival over a 22 month follow-up (74% vs 56%, 
p=O.OOS). In subsets of pts without CAD and with TC cl65 mgidl. statins were similarly 
associated with Improved survival (p=O.O06. p=O.O4 respectively). Statin Rx was an inde- 
pendent predictor of improved survival after risk-adjustment for age. sex, EF, ACEI Rx. 
renal function, and serum cardiac troponin I. 
Petra S. Niemann, Roben Robbins, Julie Shinn, L. Bing Lien?, Sung Chun, Karen J 
Friday, Stanford University, Stanford, CA 
Background: Recognlzmg that mechanical circulatoty support induces changes in myo- 
cardial contractile function and intraventricular conduction (lVC),we examined whether 
there are changes iki IVC among heart failure patients with medical therapy only. Meth- 
ods: We studied 85 consecutive patients with New York Heart Association (NYHA) class 
2 and 3 heart failure undergoing medical therapy with ACE-Inhibitors and Beta-Blockers. 
Mean follow-up bme was 452 d +/- 186( median 374 d. range 128 to 745 d). Doppler 
Echocardiograms, ECGs and clinical symptom evaluations (NYHA) were obtained in 3 to 
6 months intewalls. Results: OF 85 oatients. 79 192%) showed IVC imorovement on cur- 
face ECG following medical therapy initiation (p< 0.01). Measured effects included a 
decrease in QRS duration from 115+/- 8 to 102 +I- 6 ms lo< 0.011 a decrease in absolute 
Conclusions: Statin Rx was associated with improved survival in ischemic and non- 
ischemic HF. Randomized trials are needed for confirmation of therapeutic benefit in 
non-ischemic HF. 
QT duration from 398 +/- 12 ms to 348 +I- 7 ms (p< 0.01) and a decrease in heart rate 
from 100.6 +/- 22.6 to 65 +/-I2 ms (p< 0.01). A LBBB pattern observed in 
32(37%)patlents prior to treatment initiation resolved in 14 (43%) patients after 6 months 
of medical therapy (p-z 0.01). Improved IVC on surface ECG and echocardlographic 
changes in myocardial structure and contractile function were positively correlated. (p-z 
0.01). All echocardlographic and electrocardiographic findings could be positivly corre- 
lated with clinical symptom improvement (NYHA class 1 and 2) in 83 ( 97%) patients (p-z 
0.01). Conclustions: Electrocardiographic changes seen with medical therapy aimed to 
improve myocardial contractility in heart failure patients demonstrate that IVC and repo- 
larization are dependent on longterm myocyte contractile function and possibly on 
altered calcium homeostasis. Improved left ventricular conduction and shortened cardiac 
action potential seen with ACE-Inhibitors therapy in heart failure seems therefore rather a 
longstanding Ion channel dependent process implicating variable gene expression in the 
failing heart than a pure mechanical response to hemodynamic loading conditions of the 
left ventricle. 
1085-77 Does the Magnitude of the Beneficial Effect of Beta- 
Blockers in Chronic Heart Failure Differ Between 
Diabetic and Nondiabetic Patients? A Meta-Analysis of 
All-Cause Mortality Outcomes From Major Chronic 
Heart Failure Beta-Blocker Trials 
Steven Haas, Theo Vos, Richard Gilbert, Henn/ Krum, Monash University, Melbourne, 
Australia 
Background: Diabetes mellitus (DM) is a frequent co-motiid association of patients (pts) 
with chronic heart failure (CHF). Although CHF pts derive benefit from beta-blockers 
(BBS), these agents are still thought by many to be contraindicated amongst DM pts and 
definitive data is lacking within this sub-group. We therefore performed a meta-analysis 
of major BB CHF trials to determine the benefits (or othenvise) of BBS in DM pts with 
CHF. 
Methods: All-cause mortality data concernmg DM pts were obtained from all completed 
CHF trials of >lOOO pts randomised to BB or placebo. Trials were identified via MEDLINE 
literature searches, manual reference checks & reference texts. Results were pooled 
using the ManteCHaenszel method. 
Results: 24.8% of pts were reported as having DM in the studies analyzed. DM pts had 
increased mortakty overall c.f. non-DM pts (annualised placebo mortality rate: DM 
17.0%. non-DM 13.9%; RR: 1.22, 95% Cl: 1.07-1.39). The Impact of BBS on mortality is 
summarised in the Table. 
BBS for CHF appears to be clinically beneficial I” DM es well as non-DM pts. However, 
the benficial impact of BBS is significantly greeter in non-DM pts, by calculation of risk dif- 
ference (PcO.05). 
Discussion: CHF pts wth DM appear to derive prognostic benefit from BBS, even though 
1085-79 Sustained Hemodynamic Benefit During Long-Term 
Positive lnotropic Infusion in Patients With Advanced 
Heart Failure 
Shnkanth P. Upadva. Forrester A. Lee, Clara I. Saldarriaga. Karin Nystrom, Stuart D. 
Katz, Yale University, New Haven, CT 
Background: Long term intravenous inotropic therapy is used as a bridge to cardiac 
transplantation in patients with end-stage chronic heart failure (CHF). We aimed to deter- 
mine whether acute hemodynamic benefits were sustained during chronic therapy. 
Methodr:We analyzed serial hemodynamic data from Plpatients with advanced CHF 
(mean age 55 ys, LVEF 21%) listed for cardiac transplantation and treated with continu- 
ous home infusions of positive inotropic agents. Rest hemodynamic data before, and at 
24 hours and 3-6 months after initiation of positive inotropic therapy were compared. Ino- 
tropic agent was dobutemine in 12 subjects (mean dose 4.5 mcglkglmin. range 2.5-7.5 
mcglkglmin), milrinone in 8 subjects (mean dose 0.44 mcglkglmin, range 0.375-0.55 mcl 
kglmin), and dopamine 3 mcg&$min in 1 subject. Oral neurohormonal antagonists were 
given es tolerated. Diuretics were adjusted to maintain a non-edematous state. 
Results: lnotropic therapy acutely improved rest hemodynamics charactewed by 
decreased PA pressure, PCWP and PVR and increased cardiac index (Table). During 
chronic therapy, further reductions in PA pressure and PVR were observed without 
change in PCWP or cardiac index. 
Conclusion: Acute beneficial hemodynamic effects of positive motropic therapy were 
sustained during chronic therapy in patients with advanced CHF awatlng cardiac trans- 
plantation. Tachyphylaxis was not a clinically important factor limiting the use of continu- 
ous positive inotropic agents in these patients. 
Rcstmg bemodynamics before and during positive inotmpx infusmn 
Right Pulmonary Pulmonary Pulmonary cardiac 
atrial artey mean caplillary wedge vascualr Index 
pressure (PAM) mm pressure resistance(PVR) (Cl) I/mn/ 
(RA) Hg (PCWP) wood units In2 
mm Hg 
